Trial Profile
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Study Comparing Tivozanib Hydrochloride in Combination With Paclitaxel v Placebo in Combination With Paclitaxel in Locally Recurrent and/or Metastatic Triple Negative Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tivozanib (Primary) ; Paclitaxel
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms BATON-BC
- Sponsors AVEO Oncology
- 30 Jan 2014 Status changed from recruiting to discontinued due to insufficient enrolment as reported in an AVEO Oncology media release.
- 21 Aug 2013 New source identified and integrated (Memorial Sloan-Kettering Cancer Center; 13-047).
- 09 Aug 2013 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University, AV951-12-204).